Identification

Name
Valsartan
Accession Number
DB00177  (APRD00133)
Type
Small Molecule
Groups
Approved, Investigational
Description

Valsartan is an angiotensin-receptor blocker (ARB) that may be used to treat a variety of cardiac conditions including hypertension, diabetic nephropathy and heart failure. Valsartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Valsartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.

Structure
Thumb
Synonyms
  • (S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
  • N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
  • N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
External IDs
CGP 48933 / CGP-48933
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act ValsartanTablet80 mgOralActavis Pharma Company2011-02-16Not applicableCanada
Act ValsartanTablet40 mgOralActavis Pharma Company2011-02-16Not applicableCanada
Act ValsartanTablet160 mgOralActavis Pharma Company2011-02-16Not applicableCanada
Act ValsartanTablet320 mgOralActavis Pharma Company2011-02-16Not applicableCanada
Auro-valsartanTablet160 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Auro-valsartanTablet40 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Auro-valsartanTablet320 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Auro-valsartanTablet80 mgOralAuro Pharma Inc2014-02-06Not applicableCanada
Ava-valsartanTablet320 mgOralAvanstra Inc2011-08-182014-08-21Canada
Ava-valsartanTablet160 mgOralAvanstra Inc2011-08-182014-08-21Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-valsartanTablet80 mgOralApotex Corporation2012-07-12Not applicableCanada
Apo-valsartanTablet160 mgOralApotex Corporation2012-07-12Not applicableCanada
Apo-valsartanTablet40 mgOralApotex Corporation2012-07-12Not applicableCanada
Apo-valsartanTablet320 mgOralApotex Corporation2012-07-12Not applicableCanada
ValsartanTablet, film coated40 mg/1OralAv Kare, Inc.2015-11-12Not applicableUs
ValsartanTablet320 mg/1OralJubilant Cadista Pharmaceuticals Inc.2014-12-23Not applicableUs
ValsartanTablet80 mg/1OralAvera Mc Kennan Hospital2016-03-04Not applicableUs
ValsartanTablet40 mg/1OralAlembic Pharmaceuticals Limited2015-01-06Not applicableUs
ValsartanTablet40 mg/1OralSolco healthcare U.S., LLC2015-08-31Not applicableUs
ValsartanTablet, film coated320 mg/1OralMacleods Pharmaceuticals Limited2016-08-29Not applicableUs
International/Other Brands
Diovan
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Amlodipine and ValsartanValsartan (320 mg/1) + Amlodipine besylate (5 mg/1)Tablet, film coatedOralAlembic Pharmaceuticals Limited2016-12-01Not applicableUs
AMLODIPINE and VALSARTANValsartan (160 mg/1) + Amlodipine besylate (5 mg/1)TabletOralGavis Pharmaceuticals, LLC.2015-03-30Not applicableUs
Amlodipine and ValsartanValsartan (320 mg/1) + Amlodipine besylate (5 mg/1)Tablet, film coatedOralTeva2015-03-30Not applicableUs00093 7692 56 nlmimage10 9143c8ce
Amlodipine and ValsartanValsartan (160 mg/1) + Amlodipine besylate (5 mg/1)TabletOralAv Kare, Inc.2015-04-242017-05-03Us
Amlodipine and ValsartanValsartan (320 mg/1) + Amlodipine besylate (10 mg/1)TabletOralNovel Laboratories, Inc.2015-03-30Not applicableUs
Amlodipine and ValsartanValsartan (160 mg/1) + Amlodipine besylate (10 mg/1)Tablet, film coatedOralAlembic Pharmaceuticals Limited2016-12-01Not applicableUs
Amlodipine and ValsartanValsartan (160 mg/1) + Amlodipine besylate (10 mg/1)Tablet, film coatedOralTrigen Laboratories, Inc.2010-12-28Not applicableUs
Amlodipine and ValsartanValsartan (160 mg/1) + Amlodipine besylate (10 mg/1)Tablet, film coatedOralMylan Pharmaceuticals2015-03-30Not applicableUs
Amlodipine and ValsartanValsartan (320 mg/1) + Amlodipine besylate (10 mg/1)TabletOralAv Kare, Inc.2015-04-272017-05-03Us
Amlodipine and ValsartanValsartan (320 mg/1) + Amlodipine besylate (5 mg/1)TabletOralLupin Pharmaceuticals2015-03-30Not applicableUs
Categories
UNII
80M03YXJ7I
CAS number
137862-53-4
Weight
Average: 435.5188
Monoisotopic: 435.227039819
Chemical Formula
C24H29N5O3
InChI Key
ACWBQPMHZXGDFX-QFIPXVFZSA-N
InChI
InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1
IUPAC Name
(2S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
SMILES
CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O

Pharmacology

Indication

May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.

Structured Indications
Pharmacodynamics

Valsartan belongs to a class of antihypertensive agents called angiotensin II receptor blockers (ARBs). Valsartan is a specific and selective type-1 angiotensin II receptor (AT1) antagonist which blocks the blood pressure increasing effects angiotensin II via the renin-angiotensin-aldosterone system (RAAS). RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: AT1 and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.

Mechanism of action

Valsartan is an ARB that selectively inhibits the binding of angiotensin II to AT1, which is found in many tissues such as vascular smooth muscle and the adrenal glands. This effectively inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in a decrease in vascular resistance and blood pressure. Valsartan is selective for AT1 and has virtually no affinity for AT2. Inhibition of aldosterone secretion may inhibit sodium and water reabsorption in the kidneys while decreasing potassium excretion. The primary metabolite of valsartan, valeryl 4-hydroxy valsartan, has no pharmacological activity.

TargetActionsOrganism
AType-1 angiotensin II receptor
antagonist
Human
Absorption

Absolute bioavailability = 23% with high variability

Volume of distribution
  • 17 L (low tissue distribution)
Protein binding

94 - 97% bound to serum proteins, primarily serum albumin

Metabolism

Valsartan is excreted largely as unchanged drug (80%) and is minimally metabolized in humans. The primary circulating metabolite, 4-OH-valsartan, is pharmacologically inactive and produced CYP2C9. 4-OH-valsartan accounts for approximately 9% of the circulating dose of valsartan. Although valsartan is metabolized by CYP2C9, CYP-mediated drug-drug interactions between valsartan and other drugs is unlikely.

Route of elimination

83% of absorbed valsartan is excreted in feces and 13% is excreted in urine, primarily as unchanged drug

Half life

The initial phase t1/2 α is < 1 hour while the terminal phase t1/2 β is 5-9 hours.

Clearance
  • 2 L/h [IV administration]
  • 4.5 L/h [heart Failure patients receiving oral administration 40 to 160 mg twice a day]
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Valsartan Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Valsartan.Experimental
AbirateroneThe metabolism of Valsartan can be decreased when combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Valsartan is combined with Acebutolol.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Valsartan.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Valsartan is combined with Acemetacin.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Valsartan.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Valsartan.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Valsartan.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Valsartan is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Valsartan is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Valsartan.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Valsartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Valsartan.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Alminoprofen.Experimental
AlosetronThe metabolism of Alosetron can be decreased when combined with Valsartan.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Valsartan.Approved, Illicit, Investigational
AlprenololValsartan may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanValsartan may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineValsartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Valsartan is combined with Amiloride.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Valsartan.Approved, Withdrawn
AmiodaroneThe metabolism of Valsartan can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Valsartan.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Valsartan.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Valsartan.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Valsartan.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Valsartan is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Valsartan is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Valsartan is combined with Anisodamine.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Valsartan.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Valsartan.Approved
ApocyninThe risk or severity of adverse effects can be increased when Valsartan is combined with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Valsartan.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Valsartan is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Valsartan is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Valsartan can be increased when combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Valsartan.Experimental
ArdeparinArdeparin may increase the hyperkalemic activities of Valsartan.Approved, Withdrawn
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Valsartan.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Valsartan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Valsartan.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Valsartan.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Valsartan.Approved
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Valsartan.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Valsartan is combined with Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Azapropazone.Withdrawn
AzelastineThe metabolism of Azelastine can be decreased when combined with Valsartan.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Valsartan is combined with Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Valsartan is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Valsartan.Experimental
BarbitalBarbital may increase the hypotensive activities of Valsartan.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Valsartan.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Valsartan.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Valsartan is combined with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Valsartan is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Valsartan.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Valsartan is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Benoxaprofen.Withdrawn
BepridilValsartan may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Valsartan is combined with Betaxolol.Approved
BethanidineBethanidine may increase the hypotensive activities of Valsartan.Approved
BevoniumThe risk or severity of adverse effects can be increased when Valsartan is combined with Bevonium.Experimental
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Valsartan.Approved, Investigational
BietaserpineBietaserpine may increase the hypotensive activities of Valsartan.Experimental
BimatoprostValsartan may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Valsartan is combined with Bisoprolol.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Valsartan.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Valsartan.Approved, Investigational
BQ-123Valsartan may increase the hypotensive activities of BQ-123.Investigational
BretyliumThe risk or severity of adverse effects can be increased when Valsartan is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Valsartan.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Valsartan.Approved, Investigational
BrofaromineBrofaromine may increase the hypotensive activities of Valsartan.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Valsartan is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Valsartan.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Valsartan.Approved
BucillamineThe risk or severity of adverse effects can be increased when Valsartan is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Valsartan is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Valsartan is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Valsartan.Approved, Investigational
BupranololValsartan may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Valsartan.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Valsartan.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Valsartan.Approved
CadralazineCadralazine may increase the hypotensive activities of Valsartan.Experimental
CafedrineValsartan may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Valsartan.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Valsartan.Approved
CandesartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Candesartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Valsartan is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Valsartan can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Captopril.Approved
CarbamazepineThe metabolism of Valsartan can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Valsartan is combined with Carbaspirin calcium.Experimental
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Valsartan.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Valsartan.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Valsartan.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Valsartan is combined with Carteolol.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Valsartan.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Valsartan is combined with Castanospermine.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Valsartan.Approved, Investigational
CeliprololValsartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Valsartan can be increased when it is combined with Ceritinib.Approved
CertoparinCertoparin may increase the hyperkalemic activities of Valsartan.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Valsartan is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Valsartan is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Valsartan.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Valsartan.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Chlorthalidone.Approved
CholecalciferolThe metabolism of Valsartan can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Valsartan is combined with Choline magnesium trisalicylate.Approved
CicletanineValsartan may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Valsartan.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Valsartan.Approved
CiprofloxacinValsartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Valsartan.Approved, Investigational, Withdrawn
ClevidipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Valsartan.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Valsartan.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Valsartan is combined with Clonidine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Valsartan is combined with Clonixin.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Valsartan.Approved, Nutraceutical
CloranololValsartan may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Valsartan can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Valsartan.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Valsartan.Approved, Investigational
CrisaboroleThe metabolism of Valsartan can be decreased when combined with Crisaborole.Approved
CryptenamineValsartan may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Valsartan is combined with Curcumin.Investigational
CyclopenthiazideValsartan may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Valsartan.Approved, Investigational
CyclosporineValsartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideValsartan may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Valsartan is combined with D-Limonene.Investigational
DabrafenibThe serum concentration of Valsartan can be decreased when it is combined with Dabrafenib.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Valsartan.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Valsartan is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Valsartan.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Valsartan.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Valsartan.Approved
DelaprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Delapril.Experimental
DelavirdineThe metabolism of Valsartan can be decreased when combined with Delavirdine.Approved
DeserpidineValsartan may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Valsartan.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Valsartan is combined with Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Valsartan.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Valsartan.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Valsartan.Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Valsartan.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Valsartan is combined with Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Valsartan.Approved
diethylnorspermineValsartan may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Valsartan is combined with Difenpiramide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Valsartan is combined with Diflunisal.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Valsartan.Investigational
DiltiazemThe risk or severity of adverse effects can be increased when Valsartan is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Valsartan is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Valsartan.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Valsartan is combined with Dipyridamole.Approved
DoconexentThe metabolism of Doconexent can be decreased when combined with Valsartan.Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Valsartan.Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Valsartan.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Valsartan.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Valsartan.Approved
DosulepinThe metabolism of Valsartan can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Valsartan is combined with Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Valsartan.Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Valsartan.Approved, Illicit
DrospirenoneValsartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Valsartan is combined with Droxicam.Approved
DuloxetineValsartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Valsartan is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Valsartan is combined with E-6201.Investigational
EfavirenzThe metabolism of Valsartan can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineValsartan may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Valsartan.Approved, Investigational
EltrombopagThe serum concentration of Valsartan can be increased when it is combined with Eltrombopag.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Valsartan is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Valsartan is combined with Enalaprilat.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Valsartan.Approved
EndralazineEndralazine may increase the hypotensive activities of Valsartan.Experimental
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Valsartan.Approved
EpanololValsartan may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Valsartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Valsartan.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Valsartan.Approved
EprosartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Valsartan is combined with Esmolol.Approved
EstradiolThe metabolism of Estradiol can be decreased when combined with Valsartan.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Valsartan.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Valsartan.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Valsartan is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Valsartan is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Valsartan is combined with Ethenzamide.Experimental
EtodolacThe metabolism of Etodolac can be decreased when combined with Valsartan.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Valsartan is combined with Etofenamate.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Valsartan.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Valsartan.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Valsartan is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Valsartan is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Valsartan is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Valsartan is combined with Fenbufen.Approved
FenoldopamValsartan may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Valsartan is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Feprazone.Experimental
Ferulic acidValsartan may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Valsartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Valsartan is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Valsartan can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Valsartan can be decreased when combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Valsartan.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Valsartan.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Valsartan is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Flunoxaprofen.Experimental
FluorouracilThe metabolism of Valsartan can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Valsartan.Approved, Vet Approved
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Valsartan.Approved, Investigational
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Valsartan.Approved
FluvoxamineThe metabolism of Valsartan can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Valsartan.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Valsartan can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Valsartan.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Valsartan is combined with Furosemide.Approved, Vet Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Valsartan.Investigational
GemfibrozilThe metabolism of Valsartan can be decreased when combined with Gemfibrozil.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Valsartan.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Valsartan.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Valsartan.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Valsartan.Approved
GuacetisalThe risk or severity of adverse effects can be increased when Valsartan is combined with Guacetisal.Experimental
GuanabenzValsartan may increase the hypotensive activities of Guanabenz.Approved
GuanadrelValsartan may increase the hypotensive activities of Guanadrel.Approved
GuanazodineValsartan may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Valsartan.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Valsartan is combined with Guanfacine.Approved, Investigational
GuanoclorValsartan may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzValsartan may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanValsartan may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Valsartan.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Valsartan.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Valsartan.Experimental
HeparinHeparin may increase the hyperkalemic activities of Valsartan.Approved, Investigational
HexamethoniumValsartan may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Valsartan.Approved
HigenamineThe risk or severity of adverse effects can be increased when Valsartan is combined with Higenamine.Investigational
HistamineThe metabolism of Histamine can be decreased when combined with Valsartan.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Valsartan.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Valsartan is combined with Hydralazine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Valsartan.Approved, Vet Approved
HydroflumethiazideValsartan may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Valsartan.Approved, Illicit
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Valsartan.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Valsartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Valsartan is combined with Icatibant.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Valsartan.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Valsartan.Approved
IloprostIloprost may increase the hypotensive activities of Valsartan.Approved, Investigational
ImatinibThe metabolism of Imatinib can be decreased when combined with Valsartan.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Valsartan is combined with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Valsartan.Approved
IndapamideThe risk or severity of adverse effects can be increased when Valsartan is combined with Indapamide.Approved
IndenololValsartan may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Valsartan can be decreased when combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Valsartan.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Valsartan is combined with Indobufen.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Valsartan.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Valsartan.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Valsartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Valsartan.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Valsartan.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Valsartan.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Valsartan is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Valsartan is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Valsartan is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Valsartan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Isradipine.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Valsartan.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Kebuzone.Experimental
KetamineThe metabolism of Ketamine can be decreased when combined with Valsartan.Approved, Vet Approved
KetanserinKetanserin may increase the hypotensive activities of Valsartan.Investigational
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Valsartan.Approved
KetoconazoleThe metabolism of Valsartan can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Valsartan.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Valsartan is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Valsartan is combined with Labetalol.Approved
LacidipineValsartan may increase the hypotensive activities of Lacidipine.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Valsartan.Approved, Investigational
LatanoprostValsartan may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Valsartan.Approved, Investigational
LercanidipineValsartan may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Valsartan.Approved
LevobunololThe risk or severity of adverse effects can be increased when Valsartan is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Valsartan.Approved
LevodopaValsartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Valsartan.Approved, Investigational
LicofeloneThe metabolism of Licofelone can be decreased when combined with Valsartan.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Valsartan.Approved, Vet Approved
LinsidomineValsartan may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Valsartan is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Valsartan.Approved
LobeglitazoneThe metabolism of Valsartan can be decreased when combined with Lobeglitazone.Approved
LofexidineValsartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Valsartan is combined with Lonazolac.Experimental
LoratadineThe metabolism of Loratadine can be decreased when combined with Valsartan.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Valsartan.Approved
LosartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Losartan.Approved
LovastatinThe metabolism of Valsartan can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Loxoprofen.Approved
LumacaftorThe serum concentration of Valsartan can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Valsartan.Approved, Investigational
MacitentanValsartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Valsartan is combined with Magnesium salicylate.Approved
ManidipineValsartan may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Valsartan is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Valsartan is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Valsartan.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Valsartan is combined with Mecamylamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Valsartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Valsartan.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Valsartan.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Valsartan.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Valsartan.Investigational, Withdrawn
MesalazineThe risk or severity of adverse effects can be increased when Valsartan is combined with Mesalazine.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Valsartan.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Valsartan is combined with Metamizole.Withdrawn
MethadoneThe metabolism of Methadone can be decreased when combined with Valsartan.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Valsartan is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Valsartan.Approved
MethoserpidineValsartan may increase the hypotensive activities of Methoserpidine.Experimental
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Valsartan.Approved, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Valsartan is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Valsartan is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Valsartan.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Valsartan.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Valsartan.Approved
MetipranololThe risk or severity of adverse effects can be increased when Valsartan is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Valsartan is combined with Metoprolol.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Valsartan.Approved
MetyrosineValsartan may increase the hypotensive activities of Metyrosine.Approved
MibefradilValsartan may increase the hypotensive activities of Mibefradil.Withdrawn
MidostaurinThe metabolism of Valsartan can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Valsartan can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Valsartan.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Valsartan is combined with Minoxidil.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Valsartan.Investigational
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Valsartan.Approved
MizoribineThe risk or severity of adverse effects can be increased when Valsartan is combined with Mizoribine.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Valsartan.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Valsartan.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Valsartan.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Valsartan.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Valsartan.Approved
MuzolimineValsartan may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Valsartan is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Valsartan is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Valsartan.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Valsartan is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Valsartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Valsartan is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Valsartan is combined with Naftifine.Approved
NaftopidilValsartan may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe metabolism of Naproxen can be decreased when combined with Valsartan.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Valsartan.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Valsartan is combined with Nebivolol.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Valsartan is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Valsartan is combined with Nesiritide.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Valsartan.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Valsartan.Approved
NialamideNialamide may increase the hypotensive activities of Valsartan.Withdrawn
NicardipineThe metabolism of Valsartan can be decreased when combined with Nicardipine.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Valsartan.Approved, Vet Approved
NicorandilNicorandil may increase the hypotensive activities of Valsartan.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Valsartan.Approved
NifedipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Valsartan is combined with Niflumic Acid.Approved
NiguldipineValsartan may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineValsartan may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Valsartan is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Nisoldipine.Approved
NitrendipineValsartan may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Valsartan.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Valsartan is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Valsartan is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Valsartan is combined with Nitroprusside.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Valsartan.Approved
ObinutuzumabValsartan may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Valsartan.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Olmesartan.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Valsartan.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Valsartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Valsartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Valsartan is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Valsartan.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Valsartan.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Valsartan is combined with Orgotein.Vet Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Valsartan.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Valsartan.Approved
OxprenololValsartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Valsartan.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Valsartan is combined with Papaverine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Valsartan.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Valsartan.Approved
PargylinePargyline may increase the hypotensive activities of Valsartan.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Valsartan.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Valsartan is combined with Parthenolide.Investigational
PenbutololThe risk or severity of adverse effects can be increased when Valsartan is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Valsartan.Approved, Vet Approved
PentoliniumValsartan may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Valsartan.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Perindopril.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Valsartan.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Valsartan.Withdrawn
PhenelzinePhenelzine may increase the hypotensive activities of Valsartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Valsartan.Withdrawn
PhenobarbitalThe metabolism of Valsartan can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineValsartan may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Valsartan.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Valsartan.Approved
PhentolamineValsartan may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Valsartan.Approved, Vet Approved
PhenytoinThe metabolism of Valsartan can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Valsartan is combined with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Valsartan.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Valsartan is combined with Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Valsartan.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Valsartan.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Valsartan.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Valsartan.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Pirprofen.Experimental
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Valsartan.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Valsartan.Withdrawn
PolythiazideValsartan may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Valsartan.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Pranoprofen.Experimental
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Valsartan.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Valsartan.Approved
PrazosinThe risk or severity of adverse effects can be increased when Valsartan is combined with Prazosin.Approved
PrimidoneThe metabolism of Valsartan can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Valsartan.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Valsartan is combined with Proglumetacin.Experimental
ProguanilThe metabolism of Proguanil can be decreased when combined with Valsartan.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Valsartan.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Valsartan is combined with Propacetamol.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Valsartan.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Valsartan is combined with Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Proquazone.Experimental
PTC299The risk or severity of adverse effects can be increased when Valsartan is combined with PTC299.Investigational
PyrimethamineThe metabolism of Valsartan can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Valsartan.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Valsartan is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Quinidine can be decreased when combined with Valsartan.Approved
QuinineQuinine may increase the hypotensive activities of Valsartan.Approved
RamiprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Valsartan.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Valsartan.Approved
RemikirenValsartan may increase the hypotensive activities of Remikiren.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Valsartan is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Valsartan is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Valsartan is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Valsartan.Approved
RifampicinThe metabolism of Valsartan can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Valsartan can be increased when combined with Rifapentine.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Valsartan.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Valsartan is combined with Riociguat.Approved
RisperidoneValsartan may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabValsartan may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Valsartan.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Valsartan.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Valsartan.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Valsartan.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Valsartan.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Valsartan.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Valsartan.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Valsartan.Approved
SafrazineSafrazine may increase the hypotensive activities of Valsartan.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Valsartan is combined with Salicylamide.Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Valsartan.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Valsartan is combined with Salsalate.Approved
SaprisartanValsartan may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalThe metabolism of Valsartan can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Valsartan.Approved, Investigational, Vet Approved
SelexipagValsartan may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Valsartan is combined with Semapimod.Investigational
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Valsartan.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Valsartan is combined with Serrapeptase.Investigational
SertralineThe metabolism of Sertraline can be decreased when combined with Valsartan.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Valsartan.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Valsartan.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Valsartan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Valsartan.Approved
Sodium phosphateValsartan may increase the nephrotoxic activities of Sodium phosphate.Approved
SorafenibThe metabolism of Valsartan can be decreased when combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Valsartan is combined with Sotalol.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Valsartan is combined with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Valsartan.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Valsartan.Approved, Investigational
SulfadiazineThe metabolism of Valsartan can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Valsartan.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Valsartan.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Valsartan is combined with Sulfasalazine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Valsartan.Approved
SulfisoxazoleThe metabolism of Valsartan can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Valsartan is combined with Sulindac.Approved
SuprofenThe metabolism of Suprofen can be decreased when combined with Valsartan.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Valsartan.Approved, Investigational
TalinololValsartan may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Valsartan.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Valsartan.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Valsartan.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Valsartan is combined with Tarenflurbil.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Valsartan.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Valsartan is combined with Tenidap.Experimental
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Valsartan.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Valsartan is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Valsartan is combined with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Valsartan.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Valsartan.Withdrawn
TeriflunomideThe serum concentration of Valsartan can be increased when it is combined with Teriflunomide.Approved
TerlipressinValsartan may increase the hypotensive activities of Terlipressin.Approved, Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Valsartan.Approved, Investigational
TetrahydropalmatineValsartan may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Valsartan.Approved, Investigational, Withdrawn
TheodrenalineValsartan may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Valsartan.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Valsartan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Valsartan.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Valsartan.Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Valsartan is combined with Tiaprofenic acid.Approved
TiboloneValsartan may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe metabolism of Valsartan can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Valsartan can be decreased when combined with Ticlopidine.Approved
TicrynafenValsartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Valsartan is combined with Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Valsartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Valsartan.Approved
TizanidineThe risk or severity of adverse effects can be increased when Valsartan is combined with Tizanidine.Approved
TolazolineValsartan may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Valsartan can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Valsartan.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Valsartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Valsartan is combined with Tolmetin.Approved
TolonidineValsartan may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Valsartan.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Valsartan.Approved, Investigational
TolvaptanTolvaptan may increase the hyperkalemic activities of Valsartan.Approved
TopiroxostatThe metabolism of Valsartan can be decreased when combined with Topiroxostat.Approved
TorasemideThe risk or severity of adverse effects can be increased when Valsartan is combined with Torasemide.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Valsartan.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Valsartan is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Valsartan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Valsartan.Approved
TravoprostValsartan may increase the hypotensive activities of Travoprost.Approved
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Valsartan.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Valsartan.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Valsartan is combined with Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Valsartan is combined with Tribenoside.Experimental
TrichlormethiazideValsartan may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Valsartan.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Valsartan.Approved
TrimethaphanTrimethaphan may increase the hypotensive activities of Valsartan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Valsartan.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Valsartan.Approved
TriptolideThe risk or severity of adverse effects can be increased when Valsartan is combined with Triptolide.Investigational
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Valsartan.Withdrawn
UdenafilUdenafil may increase the antihypertensive activities of Valsartan.Approved, Investigational
UnoprostoneValsartan may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Valsartan.Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Valsartan.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Valsartan.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Valsartan.Approved
VerapamilThe risk or severity of adverse effects can be increased when Valsartan is combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Valsartan.Investigational
VincamineValsartan may increase the hypotensive activities of Vincamine.Experimental
VinpocetineValsartan may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Valsartan.Approved
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Valsartan.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Valsartan.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Valsartan.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Valsartan.Approved, Investigational, Withdrawn
XipamideValsartan may increase the hypotensive activities of Xipamide.Experimental
XylometazolineValsartan may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Valsartan.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Valsartan.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Valsartan.Approved
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Valsartan.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Valsartan.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Valsartan.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Valsartan is combined with Zofenopril.Experimental
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Valsartan.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Valsartan is combined with Zomepirac.Withdrawn
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Valsartan.Approved
Food Interactions
Not Available

References

Synthesis Reference

Zvi Harel, Igor Rukhman, "Process for the preparation of valsartan." U.S. Patent US20050010053, issued January 13, 2005.

US20050010053
General References
  1. Bader, M. (2004). Renin-angiotensin-aldosterone system. In Encyclopedic reference of molecular pharmacology (pp. 810-814). Berlin: Springer. [ISBN:9783540298328]
External Links
Human Metabolome Database
HMDB14323
KEGG Drug
D00400
PubChem Compound
60846
PubChem Substance
46509000
ChemSpider
54833
BindingDB
50049186
ChEBI
9927
ChEMBL
CHEMBL1069
Therapeutic Targets Database
DAP000363
PharmGKB
PA451848
IUPHAR
3937
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Valsartan
ATC Codes
C09DX02 — Valsartan and aliskirenC09DB08 — Valsartan and lercanidipineC10BX10 — Rosuvastatin and valsartanC09DX01 — Valsartan, amlodipine and hydrochlorothiazideC09DB01 — Valsartan and amlodipineC09DA03 — Valsartan and diureticsC09DX04 — Valsartan and sacubitrilC09CA03 — Valsartan
AHFS Codes
  • 24:32.08
PDB Entries
Not Available
FDA label
Download (237 KB)
MSDS
Download (36.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Valsartan1
1CompletedNot AvailableHyperlipidemias / Hypertensive1
1CompletedNot AvailableType 2 Diabetes Mellitus1
1CompletedBasic ScienceAdministration, Oral / Magnetic Resonance Imaging (MRI) / Pharmacokinetics1
1CompletedBasic ScienceChronic Kidney Disease (CKD) / Glomerulonephritis minimal lesion / Hypertensive1
1CompletedOtherHyperlipidemias / Hypertensive1
1CompletedSupportive CareHealthy Volunteers1
1CompletedTreatmentHealthy Male Volunteers1
1CompletedTreatmentHealthy Normotensive Volunteers1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentHyperlipidemias / Hypertensive2
1CompletedTreatmentHypertensive1
1CompletedTreatmentType 2 Diabetes Mellitus1
1RecruitingTreatmentType 2 Diabetes Mellitus1
1Unknown StatusTreatmentHealthy Volunteers1
1WithdrawnTreatmentHypertensive / Metabolic Syndromes1
2CompletedNot AvailableSalt-sensitive Hypertension1
2CompletedBasic ScienceHypertensive1
2CompletedTreatmentAlport Syndrome1
2CompletedTreatmentAtherosclerosis / Carotid Artery Diseases1
2CompletedTreatmentChronic Heart Failure (CHF)2
2CompletedTreatmentComplication of Hemodialysis / End Stage Renal Failure on Dialysis1
2CompletedTreatmentHypertension,Essential3
2CompletedTreatmentHypertensive5
2CompletedTreatmentMyocardial Ischemia / Post Acute Coronary Syndrome1
2CompletedTreatmentSystolic Hypertension1
2Not Yet RecruitingTreatmentPeripheral Arterial Disease (PAD)1
2RecruitingTreatmentDiastolic Dysfunction1
2RecruitingTreatmentHypertrophic Cardiomyopathy1
2TerminatedPreventionAging / Angiotensin Receptor Antagonists / Human Immunodeficiency Virus (HIV) / Sarcopenia1
2, 3CompletedTreatmentHypertension,Essential1
3Active Not RecruitingTreatmentHeart Failure With Preserved Ejection Fraction (HFpEF)1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus1
3CompletedTreatmentChronic Kidney Disease (CKD) / Hypertensive1
3CompletedTreatmentDiabetes2
3CompletedTreatmentDyslipidemias / Hypercholesterolaemia / Hypertensive1
3CompletedTreatmentDyslipidemias / Hypertensive1
3CompletedTreatmentHypercholesterolaemia / Hypertension,Essential1
3CompletedTreatmentHypercholesterolaemia / Hypertensive1
3CompletedTreatmentHyperlipidemias / Hypertensive1
3CompletedTreatmentHypertension,Essential2
3CompletedTreatmentHypertension; Hypertrophy, Left Ventricular1
3CompletedTreatmentHypertensive37
3CompletedTreatmentHypertensive / Metabolic Syndromes1
3CompletedTreatmentNonvalvular Atrial Fibrillation1
3CompletedTreatmentPediatric Hypertension With or Without CKD1
3CompletedTreatmentStage 1 Hypertension / Stage 2 Hypertension1
3RecruitingTreatmentAcute Myocardial Infarction (AMI)1
3RecruitingTreatmentChronic Heart Failure With Reduced Ejection Fraction (HFrEF)1
3RecruitingTreatmentHeart Failure With Preserved Ejection Fraction (HFpEF)1
3RecruitingTreatmentHeart Failure, Unspecified1
3RecruitingTreatmentHypertension,Essential1
3TerminatedHealth Services ResearchEndothelial Dysfunction / Oxidative Stress1
3TerminatedTreatmentHypertensive1
3WithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kidney Diseases1
4Active Not RecruitingBasic ScienceArterial hypoxia / Obstructive Sleep Apnea (OSA) / Sleep Apnea Syndrome1
4Active Not RecruitingSupportive CareHearth Failure With Reduced Ejection Fraction (HFrEF)1
4Active Not RecruitingTreatmentBlood Pressures / Stroke, Ischemic1
4Active Not RecruitingTreatmentMitral Valve Insufficiency / Symptomatic left ventricular ejection fraction ≤ 35% Chronic heart failure1
4CompletedBasic ScienceType 2 Diabetes Mellitus1
4CompletedDiagnosticCongestive Heart Failure (CHF) / Hypertensive / Ischaemic Heart Diseases / Strokes1
4CompletedPreventionHypertensive / Type 2 Diabetes Mellitus1
4CompletedPreventionNon-Hodgkin's Lymphoma (NHL)1
4CompletedTreatmentAlbuminuria / Hypertensive / Type 2 Diabetes Mellitus1
4CompletedTreatmentBlood Pressures1
4CompletedTreatmentChronic Kidney Disease (CKD) / Hypertensive1
4CompletedTreatmentCongestive Cardiomyopathy1
4CompletedTreatmentCongestive Heart Failure (CHF) / Hypertensive1
4CompletedTreatmentCoronary Artery Disease1
4CompletedTreatmentCoronary Artery Disease / Diabetes / Hypertensive1
4CompletedTreatmentCoronary Artery Disease / Hypertensive / Type 2 Diabetes Mellitus1
4CompletedTreatmentDiabetes / Hypertensive / Proteinuria1
4CompletedTreatmentDiabetic Nephropathies / Hypertensive2
4CompletedTreatmentDiastolic Dysfunction, Symptomatic Heart Failure1
4CompletedTreatmentDiastolic Dysfunction / Hypertensive2
4CompletedTreatmentDyslipidemias / Hypertensive1
4CompletedTreatmentEssential,Hypertension1
4CompletedTreatmentGlomerulonephritis / IgA Nephropathy1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHeart Failure, Unspecified / Ventricular Dysfunction, Left1
4CompletedTreatmentHigh Blood Pressure1
4CompletedTreatmentHigh Blood Pressure / Hypertensive1
4CompletedTreatmentHypertension, Dyslypidaemia1
4CompletedTreatmentHypertension,Essential3
4CompletedTreatmentHypertensive34
4CompletedTreatmentHypertensive / Impaired Glucose Tolerance (IGT)1
4CompletedTreatmentHypertensive / Left Ventricular Hypertrophy1
4CompletedTreatmentHypertensive / Metabolic Syndromes1
4CompletedTreatmentHypertensive / Proteinuria / Type 2 Diabetes Mellitus1
4CompletedTreatmentMicroalbuminuria / Proteinuria1
4CompletedTreatmentMyocardial Infarction (MI)1
4CompletedTreatmentStage 2 Hypertension1
4CompletedTreatmentStage 2 Systolic Hypertension1
4Not Yet RecruitingTreatmentCongestive Heart Failure (CHF) / Hypertensive1
4Not Yet RecruitingTreatmentHeart Failure, Unspecified1
4RecruitingNot AvailableHeart Failure With Reduced Ejection Fraction (HFrEF)1
4RecruitingOtherHeart Failure, Unspecified1
4RecruitingPreventionBlood Pressures / Hypertension Complicated / Left Ventricular Hypertrophy1
4RecruitingPreventionBlood Pressures / Hypertensive / Strokes1
4RecruitingPreventionBone destruction / Cardiovascular Disease (CVD) / Deficiency, Vitamin D / Secondary Hyp1
4RecruitingPreventionFirst Time Dual Chamber Pacemaker Implantation1
4RecruitingSupportive CareAcute Heart Failure (AHF)1
4RecruitingTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes1
4RecruitingTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF)1
4RecruitingTreatmentHeart Failure, Unspecified3
4RecruitingTreatmentHypertensive1
4RecruitingTreatmentPrimary IgA Nephropathy1
4TerminatedPreventionHypertensive1
4TerminatedTreatmentDiabetic Nephropathies / Glomerulonephritis, Membranous / Glomerulopathy (Obesity-associated) / Glomerulosclerosis, Focal Segmental / Hypertensive Nephrosclerosis / IgA Nephropathy / Proteinuric Kidney Disease1
4TerminatedTreatmentDiabetic Nephropathies / Hypertensive1
4TerminatedTreatmentNonvalvular Atrial Fibrillation1
4Unknown StatusDiagnosticChronic Kidney Disease (CKD) / Proteinuria1
4Unknown StatusPreventionBMI >30 kg/m2 / Hypertensive1
4Unknown StatusTreatmentAcute Ischemic Stroke (AIS)1
4Unknown StatusTreatmentAlbuminuria / Diabetes Mellitus (DM) / Hypertensive1
4Unknown StatusTreatmentChronic Kidney Disease (CKD)1
4Unknown StatusTreatmentCongestive Heart Failure (CHF) / Hypertensive / Ischaemic Heart Diseases1
4Unknown StatusTreatmentDiabetes Mellitus (DM)1
4Unknown StatusTreatmentHypertension,Essential1
4Unknown StatusTreatmentLipotoxicity / Metabolic Syndromes1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentSmall Abdominal Aortic Aneurysm1
4WithdrawnTreatmentStroke, Acute1
Not AvailableActive Not RecruitingTreatmentRenal Dysfunction / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableHealthy Normotensive Participants2
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedTreatmentRenal Function Disorder1
Not AvailableRecruitingNot AvailableHeart Failure, Unspecified1
Not AvailableRecruitingNot AvailableLower Leg Edema / Orthostatic Hypertension1
Not AvailableRecruitingOtherChronic Heart Failure (CHF) / Sleep Apnea Syndrome1
Not AvailableRecruitingTreatmentCongestive Heart Failure (CHF)1
Not AvailableTerminatedTreatmentAortic Compliance / Diastolic Function / Insulin Sensitivity1
Not AvailableTerminatedTreatmentHypertensive / Microvascular Angina1
Not AvailableUnknown StatusNot AvailableHypertensive1
Not AvailableWithdrawnTreatmentCerebrovascular Accidents1

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
  • Novartis Corporation
Packagers
Dosage forms
FormRouteStrength
TabletOral
TabletOral320 mg
TabletOral40 mg
CapsuleOral160 mg
TabletOral160 mg
CapsuleOral80 mg
TabletOral80 mg
Tablet, film coatedOral
TabletOral160 mg/1
TabletOral320 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
Tablet, film coatedOral160 mg/1
Tablet, film coatedOral320 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral80 mg/1
Prices
Unit descriptionCostUnit
Diovan hct 320-25 mg tablet4.63USD tablet
Diovan hct 320-12.5 mg tablet4.1USD tablet
Diovan hct 160-25 mg tablet3.66USD tablet
Diovan hct 160-12.5 mg tablet3.27USD tablet
Diovan 320 mg tablet3.17USD tablet
Diovan hct 80-12.5 mg tablet3.0USD tablet
Diovan 160 mg tablet2.42USD tablet
Diovan 80 mg tablet2.33USD tablet
Diovan 40 mg tablet2.32USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5399578No1995-03-212012-03-21Us
CA2259148No2009-09-292017-06-18Canada
CA2036427No1998-12-292011-02-15Canada
US6294197Yes1997-12-182017-12-18Us
US5559111No1998-07-212018-07-21Us
US6395728No1999-07-082019-07-08Us
US5972990Yes1997-04-262017-04-26Us
US8168616No2006-07-032026-07-03Us
US8101599No2003-05-162023-05-16Us
US8475839Yes2003-11-162023-11-16Us
US8796331No2003-01-142023-01-14Us
US8101659No2003-01-142023-01-14Us
US7468390No2003-11-272023-11-27Us
US8404744No2003-01-142023-01-14Us
US8877938No2007-05-272027-05-27Us
US7803838No2006-08-292026-08-29Us
US7838552No2007-10-042027-10-04Us
US9388134No2006-11-082026-11-08Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)116-117 °CNot Available
logP5.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0234 mg/mLALOGPS
logP3.68ALOGPS
logP5.27ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)4.37ChemAxon
pKa (Strongest Basic)-0.11ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area112.07 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity134.77 m3·mol-1ChemAxon
Polarizability47.27 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9956
Blood Brain Barrier-0.8032
Caco-2 permeable-0.6912
P-glycoprotein substrateSubstrate0.685
P-glycoprotein inhibitor INon-inhibitor0.5548
P-glycoprotein inhibitor IINon-inhibitor0.5966
Renal organic cation transporterNon-inhibitor0.8646
CYP450 2C9 substrateNon-substrate0.7722
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5073
CYP450 1A2 substrateNon-inhibitor0.8707
CYP450 2C9 inhibitorNon-inhibitor0.5398
CYP450 2D6 inhibitorNon-inhibitor0.8816
CYP450 2C19 inhibitorInhibitor0.5539
CYP450 3A4 inhibitorNon-inhibitor0.5521
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5618
Ames testNon AMES toxic0.6384
CarcinogenicityNon-carcinogens0.645
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6518 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9766
hERG inhibition (predictor II)Non-inhibitor0.7388
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-001i-0000900000-45397dbc5403f1111d85
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-003r-0303900000-1056988fef13dc9becc8
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-004i-0900000000-65d8dfbf9280fcea77fb
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-004i-0900000000-77a9588a3e936c9d2e28
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0009000000-160f82ad0952fc9b3350
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-0000900000-d7bf9d8976f47e44ab4a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0fb9-0915000000-1f5a4e134cd8450810e7
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0900000000-19095db3835430e9fe16
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0900000000-00e9b9924b37c4db7a8d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0900000000-fb8741bb91ee87d8245e
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-0000900000-be5ab1c8cde8851235e3
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0fb9-0915000000-08501c181e1066f2aa0a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0900000000-6cabcfa5948837eddb2e
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0900000000-d0aedd0bab06b374571a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0901000000-a4572421f0a393f299a1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0009000000-0f743f9e78dce83f2414
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-003r-0912600000-feeef5a05d8ef569460d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0022900000-07c84eac301d580a8bea
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4u-0190000000-8a48f701b19b54e7ebf9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4u-0190000000-34257438319cae238dcb
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0590000000-403ef14fce06289de8e7
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a59-0960000000-d4e79af5b474f613f6e9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-052u-0093000000-ee050d1727838e542ce7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-066r-0013900000-27f31e9591de9c0d036b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4u-0096600000-2c9e5fef1cb7e2e64e67
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4u-0091000000-0bff344a92ee0cc41b8f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0390000000-fa2f74ef15c1a6b93838
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a59-0960000000-ca847cc390cd0e68c6b6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pec-0920000000-5c29e64b37c8cde1c7ba
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ziu-0910000000-08f3eecf83a71f4fb485
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4u-0096600000-598ea56da3433ecd4bab
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4u-0091000000-0aaf7a6567cb3745cb23
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0490000000-4b8d8ce6d0a486599b71
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a59-0950000000-6cd1be141d3f05844a75
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pec-0920000000-053a50818908a33699b3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ziu-0910000000-c10b0879c877503826c5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-066r-0013900000-af025bf00303b40b6d48
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0122900000-e2d5ae1b4433254a8ebe
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4u-1492000000-bc19c44b1bd382b3180f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0012900000-1b87098801f65211057a
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4u-0392000000-5823d4f7c41e4fd6208b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4u-0391100000-8997765a9ed3c9424c07

Taxonomy

Description
This compound belongs to the class of organic compounds known as valine and derivatives. These are compounds containing valine or a derivative thereof resulting from reaction of valine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Valine and derivatives
Alternative Parents
N-acyl-L-alpha-amino acids / Biphenyls and derivatives / Phenyltetrazoles and derivatives / N-acyl amines / Tertiary carboxylic acid amides / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds
show 4 more
Substituents
N-acyl-alpha-amino acid / Valine or derivatives / N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / Biphenyl / Phenyltetrazole / Monocyclic benzene moiety / N-acyl-amine / Benzenoid / Azole
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monocarboxylic acid, monocarboxylic acid amide, biphenylyltetrazole (CHEBI:9927)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name
AGTR1
Uniprot ID
P30556
Uniprot Name
Type-1 angiotensin II receptor
Molecular Weight
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S, Camisasca RP: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004 Dec;15(12):3126-33. [PubMed:15579516]
  3. Criscione L, de Gasparo M, Buhlmayer P, Whitebread S, Ramjoue HP, Wood J: Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol. 1993 Oct;110(2):761-71. [PubMed:8242249]
  4. Shargorodsky M, Leibovitz E, Lubimov L, Gavish D, Zimlichman R: Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension. Am J Hypertens. 2002 Dec;15(12):1087-91. [PubMed:12460705]
  5. de Gasparo M, Whitebread S: Binding of valsartan to mammalian angiotensin AT1 receptors. Regul Pept. 1995 Nov 10;59(3):303-11. [PubMed:8577935]
  6. Siragy HM, El-Kersh MA, De Gasparo M, Webb RL, Carey RM: Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP. J Hypertens. 2002 Jun;20(6):1157-63. [PubMed:12023686]
  7. Stanfield, Cindy L.;Germann, William J. (2009). Principles of Human Physiology (3rd ed.). Benjamin-Cummings Publishing Company. [ISBN:978-0321556660]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Nakashima A, Kawashita H, Masuda N, Saxer C, Niina M, Nagae Y, Iwasaki K: Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes. Xenobiotica. 2005 Jun;35(6):589-602. [PubMed:16192110]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Poirier A, Cascais AC, Funk C, Lave T: Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):585-611. doi: 10.1007/s10928-009-9139-3. Epub 2009 Nov 20. [PubMed:19936896]
  2. Poirier A, Cascais AC, Funk C, Lave T: Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. Chem Biodivers. 2009 Nov;6(11):1975-87. doi: 10.1002/cbdv.200900116. [PubMed:19937834]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Poirier A, Cascais AC, Funk C, Lave T: Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):585-611. doi: 10.1007/s10928-009-9139-3. Epub 2009 Nov 20. [PubMed:19936896]
  2. Poirier A, Cascais AC, Funk C, Lave T: Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. Chem Biodivers. 2009 Nov;6(11):1975-87. doi: 10.1002/cbdv.200900116. [PubMed:19937834]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:32